Physician profile
Mack Rachal
NPI 1902856370
$259,568.65
in general payments reported to CMS, 2019-2025
31 companies · $11K in 2025
The $11K reported for 2025 was more than what 92% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115K · 2020: $31K · 2021: $23K · 2022: $47K · 2023: $10K · 2024: $22K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $37K · Travel and Lodging: $3,550 · Food and Beverage: $3,131 · Education: $303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36,751.50 |
| Travel and Lodging | $3,549.77 |
| Food and Beverage | $3,130.75 |
| Education | $303.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $183,399.87 | 2019-2025 | |
| Helsinn Therapeutics (U.S.), INC. | $65,848.27 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $2,671.07 | 2019-2024 | |
| Genzyme Corporation | $1,692.93 | 2019-2025 | |
| Janssen Biotech, INC. | $1,014.89 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $712.16 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $635.51 | 2020-2025 | Dupixent |
| Ucb Biosciences INC. | $628.56 | 2020 | |
| Galderma Laboratories, L.P. | $498.11 | 2019-2025 | Nemluvio, Oracea, Epsolay |
| Ucb, INC. | $473.61 | 2019-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $349.18 | 2019-2025 | Ilumya |
| Pfizer INC. | $340.36 | 2019-2024 | |
| Amgen INC. | $300.47 | 2020-2022 | |
| Leo Pharma INC. | $174.16 | 2020-2024 | Adbry |
| Janssen Scientific Affairs, LLC | $124.64 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $123.30 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $107.43 | 2019-2021 | |
| Celgene Corporation | $105.62 | 2019 | |
| Kyowa Kirin, INC. | $52.66 | 2019-2021 | |
| Dermavant Sciences, INC. | $51.18 | 2023 | Vtama |
| Medimetriks Pharmaceuticals, INC. | $49.05 | 2019 | |
| Organon LLC | $42.42 | 2025 | |
| Novo Nordisk INC | $35.73 | 2021-2022 | |
| Epi Health, LLC | $34.95 | 2021 | |
| Dermira, INC. | $28.18 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.82 | 2021 | |
| Dynavax Technologies Corporation | $16.65 | 2020 | |
| Sanofi Pasteur INC. | $13.38 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.79 | 2019 | |
| Merck Sharp & Dohme LLC | $11.70 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mack Rachal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.